Major U.S. integrated cancer care provider 21st Century Oncology has officially become part of GenesisCare’s leading international oncology network. The combined group plans to increase access to high quality cancer care services for patients across U.S. communities.
Australian-headquartered GenesisCare specialises in the delivery of oncology treatment, and today becomes one of the largest networks of integrated oncology care in the world, with treatment centres and clinics across the U.S., Australia, the U.K. and Spain.
Patients will benefit from an increased investment in the latest treatment technology, along with the combined experience of 21st Century Oncology’s specialists and GenesisCare’s international clinical network.
GenesisCare Chief Executive Officer, Dan Collins, is excited for GenesisCare to lead cancer care delivery in the U.S.: “Since day one, improving our patients’ clinical outcomes and their care experience has been our top priority,” Mr Collins said.
“GenesisCare is delighted to partner alongside the leading physicians and specialist teams at 21st Century Oncology. Together, we can deliver a profound positive impact for cancer patients, not only across America, but around the world.”
The combined group of more than 5,000 doctors, specialists and team will reach over 400,000 patients across 440 locations internationally each year. This includes GenesisCare’s cardiac services in Australia.
“We have exciting long-term growth plans in the U.S. Our vision is to ensure as many cancer patients as possible receive the right outcome, at the right time close to home. Our goal is to make it easier for everyone,” Mr Collins said.
GenesisCare has committed to installing 10 state-of-the-art linear accelerators in the first 100 days, which are critical to the delivery of highly targeted radiation therapy, at locations across Florida, South Carolina, North Carolina and Rhode Island.
Commenting on completing this transaction during a global pandemic, Mr Collins said that employee and patient safety has been critical to ensuring GenesisCare’s ability to treat patients during this crisis.
“Cancer doesn’t stop, and we haven’t either. We couldn’t be prouder of our fantastic teams who have adapted to new ways of working, including even greater safety measures, use of digitally enabled care, and other innovative solutions to keep our teams and patients safe and our centres open when it matters most,” he said.
This acquisition comes on the heels of the announcement on Friday that Landmark Cancer Center had joined 21st Century Oncology.
GenesisCare Chairman Dr Brian McNamee said GenesisCare had successfully improved patient access to high quality care in Australia and Europe and would do the same in the US.
“This new combination is well positioned to be best in class in the U.S, to deliver world class patient care and access, and continued growth,” Dr McNamee said.
“I have a belief in the people and the game plan, and this highly skilled, determined group will achieve amazing outcomes for patients in the world’s largest healthcare market.”
21st Century Oncology CEO, Kim Commins-Tzoumakas, welcomed the combination with GenesisCare.
“Our physicians and team have been waiting for this day to realise a whole range of wonderful initiatives very quickly which will further enhance quality of care and access for cancer patients across the country. GenesisCare has proven its credentials as a trusted partner in Australia and Europe, and cancer care in the U.S. will now be transformed.
“Following a transition over the next few months, I am thrilled to hand over the reins to the GenesisCare team and my very strong leadership team while I move to a Board role with GenesisCare in the United States. I am so proud of what we have done that brought us here and am looking forward to being part of the team leading the strategy with GenesisCare going forward,” Ms Commins-Tzoumakas said.
The sale of 21st Century Oncology officially closed today, following customary regulatory reviews.
GenesisCare continues to be led by founder and CEO Dan Collins.